{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:55:27Z","timestamp":1777575327555,"version":"3.51.4"},"reference-count":144,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.autrev.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T23:57:42Z","timestamp":1434153462000},"page":"903-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients"],"prefix":"10.1016","volume":"14","author":[{"given":"Brit","family":"Fitzner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe Klaus","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.06.001_bb0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756285613501575","article-title":"Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner","volume":"7","author":"Oreja-Guevara","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2015.06.001_bb0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2014.01.012","article-title":"Revised diagnostic criteria of multiple sclerosis","volume":"13","author":"Milo","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.06.001_bb0015","first-page":"275","article-title":"Inflammation, demyelination, and degeneration \u2014 recent insights from MS pathology","volume":"2011","author":"Stadelmann","year":"1812","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2015.06.001_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1155\/2013\/484959","article-title":"Clinical, MRI, and CSF markers of disability progression in multiple sclerosis","volume":"35","author":"Gajofatto","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.autrev.2015.06.001_bb0040","first-page":"922","article-title":"Diagnosis and differential diagnosis of multiple sclerosis","volume":"19","author":"Katz Sand","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.autrev.2015.06.001_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.22508","article-title":"Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis","volume":"70","author":"Tumani","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2015.06.001_bb0055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/awh176","article-title":"Development of biomarkers in multiple sclerosis","volume":"127","author":"Bielekova","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2015.06.001_bb0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood\u2013brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0065","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0070","first-page":"246412","article-title":"Consensus guidelines for CSF and blood biobanking for CNS biomarker studies","volume":"2011","author":"Teunissen","year":"2011","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.autrev.2015.06.001_bb0075","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0080","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0b013e3182143345","article-title":"After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage","volume":"76","author":"Giovannoni","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2009.04.010","article-title":"Cerebrospinal fluid biomarkers in multiple sclerosis","volume":"35","author":"Tumani","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.autrev.2015.06.001_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF03256329","article-title":"Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making","volume":"13","author":"Harris","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.autrev.2015.06.001_bb0095","first-page":"340508","article-title":"Biomarkers in multiple sclerosis: an up-to-date overview","volume":"2013","author":"Katsavos","year":"2013","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.autrev.2015.06.001_bb0100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.pneurobio.2011.04.007","article-title":"Development of biomarkers for multiple sclerosis as a neurodegenerative disorder","volume":"95","author":"Ziemann","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.06.001_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1155\/2006\/709869","article-title":"Biomarkers indicative of blood\u2013brain barrier disruption in multiple sclerosis","volume":"22","author":"Waubant","year":"2006","journal-title":"Dis Markers"},{"key":"10.1016\/j.autrev.2015.06.001_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","article-title":"Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness","volume":"180","author":"Link","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0120","series-title":"Multiple sclerosis & cerebrospinal fluid","author":"Zettl","year":"2005"},{"key":"10.1016\/j.autrev.2015.06.001_bb0125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2015.06.001_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-5728(00)00292-7","article-title":"Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis","volume":"108","author":"Sellebjerg","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0135","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/jnnp.2005.086116","article-title":"Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis","volume":"77","author":"Perini","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2015.06.001_bb0140","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1212\/WNL.58.5.824","article-title":"Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS","volume":"58","author":"Villar","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00415-008-0827-5","article-title":"A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease","volume":"255","author":"Mandrioli","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.59.4.555","article-title":"Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS","volume":"59","author":"Villar","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.10441","article-title":"Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis","volume":"53","author":"Villar","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0160","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1468-1331.2007.01871.x","article-title":"Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event","volume":"14","author":"Schneider","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0404.2008.01058.x","article-title":"High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid","volume":"119","author":"Arneth","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2015.06.001_bb0170","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.2003.010710","article-title":"Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis","volume":"75","author":"Goffette","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2015.06.001_bb0175","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s00415-008-0954-z","article-title":"Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis","volume":"255","author":"Presslauer","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0180","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1212\/01.wnl.0000238107.31364.21","article-title":"Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis","volume":"67","author":"Rinker","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00415-006-0185-0","article-title":"Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis","volume":"254","author":"Bartos","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/01.WNL.0000041496.58127.E3","article-title":"Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy","volume":"60","author":"Eikelenboom","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0195","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1212\/WNL.58.9.1372","article-title":"Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit","volume":"58","author":"Silber","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0404.2006.00794.x","article-title":"Antibodies against light neurofilaments in multiple sclerosis patients","volume":"116","author":"Bartos","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2015.06.001_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jneuroim.2013.06.010","article-title":"Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis","volume":"262","author":"Fialov\u00e1","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0210","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ana.20276","article-title":"Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients","volume":"56","author":"Sueoka","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0215","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13550280701883840","article-title":"Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis","volume":"14","author":"Yukitake","year":"2008","journal-title":"J Neurovirol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0220","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.autrev.2014.07.002","article-title":"Targets of the humoral autoimmune response in multiple sclerosis","volume":"13","author":"Fraussen","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.06.001_bb0225","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial","volume":"64","author":"Bar-Or","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0235","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1073\/pnas.0510672103","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis","volume":"103","author":"Lalive","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.06.001_bb0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0245","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0607242103","article-title":"Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis","volume":"103","author":"Zhou","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.06.001_bb0250","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0255","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.172.1.661","article-title":"Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis","volume":"172","author":"Guggenmos","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0260","series-title":"High-density peptide microarray analysis of IgG autoantibody reactivities in serum and cerebrospinal fluid of multiple sclerosis patients","author":"Hecker","year":"2015"},{"key":"10.1016\/j.autrev.2015.06.001_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2005.10.009","article-title":"Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis","volume":"241","author":"Chiba","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.06.001_bb0270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2015.06.001_bb0275","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000330240","article-title":"Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica","volume":"19","author":"Long","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.autrev.2015.06.001_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa1110740","article-title":"Potassium channel KIR4.1 as an immune target in multiple sclerosis","volume":"367","author":"Srivastava","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.06.001_bb0285","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ana.24168","article-title":"Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions","volume":"75","author":"Schirmer","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fneur.2014.00062","article-title":"KIR4.1 antibodies as biomarkers in multiple sclerosis","volume":"5","author":"Wunsch","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0295","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1177\/1352458514531086","article-title":"Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis","volume":"20","author":"Nerrant","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0300","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(14)70141-3","article-title":"Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study","volume":"13","author":"Brickshawana","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0305","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1073858410386615","article-title":"Viruses and multiple sclerosis","volume":"17","author":"Owens","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.autrev.2015.06.001_bb0310","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI200523661","article-title":"Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis","volume":"115","author":"Cepok","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.06.001_bb0315","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jneuroim.2012.09.007","article-title":"The antibody response to Epstein-Barr virions is altered in multiple sclerosis","volume":"254","author":"Lindsey","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0320","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2011.06.012","article-title":"Intrathecal human herpes virus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid","volume":"237","author":"Virtanen","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0325","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13550280701381332","article-title":"Evidence for human herpes virus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications","volume":"13","author":"Virtanen","year":"2007","journal-title":"J Neurovirol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0330","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-005-0794-z","article-title":"Intrathecal antibody (IgG) production against human herpes virus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response","volume":"252","author":"Derfuss","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0335","doi-asserted-by":"crossref","first-page":"e40431","DOI":"10.1371\/journal.pone.0040431","article-title":"Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis","volume":"7","author":"Brecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.06.001_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2012.03.014","article-title":"Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome","volume":"247","author":"Ahlgren","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/gene.2011.42","article-title":"Epstein-Barr virus and multiple sclerosis: interaction with HLA","volume":"13","author":"Sundqvist","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2015.06.001_bb0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.05.009","article-title":"Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab","volume":"261","author":"Lin","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0355","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"The CSF JCV antibody index for diagnosis of natalizumab-associated PML","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0365","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40291-014-0117-0","article-title":"Biomarkers of therapeutic response in multiple sclerosis: current status","volume":"18","author":"Harris","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.autrev.2015.06.001_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0375","doi-asserted-by":"crossref","first-page":"970789","DOI":"10.1155\/2012\/970789","article-title":"Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis","volume":"2012","author":"Chen","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0385","doi-asserted-by":"crossref","first-page":"287ra74","DOI":"10.1126\/scitranslmed.aaa8038","article-title":"Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis","volume":"7","author":"Cao","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2015.06.001_bb0390","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awp289","article-title":"Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis","volume":"132","author":"Brucklacher-Waldert","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2015.06.001_bb0395","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuroscience.2013.01.020","article-title":"Soluble CD146 in cerebrospinal fluid of active multiple sclerosis","volume":"235","author":"Duan","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.autrev.2015.06.001_bb0400","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00415-011-5973-5","article-title":"Central inflammation versus peripheral regulation in multiple sclerosis","volume":"258","author":"Edwards","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0405","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2015.06.001_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.03.026","article-title":"Biomarkers of disease activity in multiple sclerosis","volume":"305","author":"Graber","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.06.001_bb0415","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestr\u00f6m","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0420","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1212\/WNL.0b013e3181a0fe3f","article-title":"Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis","volume":"72","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0425","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0430","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/ane.12151","article-title":"Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis","volume":"128","author":"Kuhle","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2015.06.001_bb0435","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing\u2013remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0440","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0445","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0450","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0455","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/1352458507076406","article-title":"Cerebrospinal fluid proteome profile in multiple sclerosis","volume":"13","author":"Lehmensiek","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0460","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jprot.2010.01.004","article-title":"Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers","volume":"73","author":"Ottervald","year":"2010","journal-title":"J Proteomics"},{"key":"10.1016\/j.autrev.2015.06.001_bb0465","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1177\/1352458513477923","article-title":"Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis","volume":"19","author":"Harris","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0470","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neulet.2009.01.057","article-title":"CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis","volume":"452","author":"Tumani","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2015.06.001_bb0475","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00415-004-0336-0","article-title":"Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG","volume":"251","author":"Bartosik-Psujek","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0480","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s00415-004-0524-y","article-title":"CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS","volume":"251","author":"Mart\u00ednez-Y\u00e9lamos","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0485","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.57.4.722","article-title":"14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis","volume":"57","author":"Mart\u00ednez-Y\u00e9lamos","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0490","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1742-2094-9-215","article-title":"Cellular sources of dysregulated cytokines in relapsing\u2013remitting multiple sclerosis","volume":"9","author":"Romme Christensen","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2015.06.001_bb0495","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s00415-014-7507-4","article-title":"N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis","volume":"261","author":"Trentini","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0500","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1023\/A:1007608615682","article-title":"Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases","volume":"25","author":"Greco","year":"2000","journal-title":"Neurochem Res"},{"key":"10.1016\/j.autrev.2015.06.001_bb0505","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0165-5728(03)00204-2","article-title":"Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS","volume":"140","author":"Correale","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0510","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00415-005-0618-1","article-title":"Intrathecal sICAM-1 production in multiple sclerosis\u2014correlation with triple dose Gd-DTPA MRI enhancement and IgG index","volume":"252","author":"Acar","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0515","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneurol.2011.148","article-title":"Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood\u2013brain barrier breakdown in neuromyelitis optica","volume":"68","author":"Uzawa","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0520","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nbd.2010.06.007","article-title":"Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis","volume":"40","author":"Harris","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.autrev.2015.06.001_bb0525","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.cellsig.2013.03.016","article-title":"Diverse pathological implications of YKL-40: answers may lie in \u201coutside-in\u201d signaling","volume":"25","author":"Prakash","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.autrev.2015.06.001_bb0530","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2015.06.001_bb0535","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1352458510392619","article-title":"Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis","volume":"17","author":"Correale","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0540","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2014.02.004","article-title":"CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment","volume":"269","author":"Malmestr\u00f6m","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0545","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/brain\/awq035","article-title":"Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis","volume":"133","author":"Comabella","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2015.06.001_bb0550","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/pr3012107","article-title":"Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients","volume":"12","author":"Stoop","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.autrev.2015.06.001_bb0555","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.autrev.2015.04.008","article-title":"Revisiting the role of mast cells in autoimmunity","volume":"14","author":"Yu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.06.001_bb0560","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.nbd.2009.11.014","article-title":"Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery?","volume":"37","author":"Brynedal","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.autrev.2015.06.001_bb0565","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0570","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","article-title":"The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers","volume":"16","author":"Khademi","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0575","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jneuroim.2005.10.002","article-title":"Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis","volume":"171","author":"Muraro","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0580","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","article-title":"Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis","volume":"81","author":"Warnke","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0585","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.4049\/jimmunol.170.9.4846","article-title":"Complementarity-determining region 3 spectra typing analysis of the TCR repertoire in multiple sclerosis","volume":"170","author":"Matsumoto","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0590","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1212\/WNL.0b013e3182759621","article-title":"Regulated microRNAs in the CSF of patients with multiple sclerosis. A case\u2013control study","volume":"79","author":"Haghikia","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.06.001_bb0595","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0600","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1352458514520911","article-title":"The potential role of epigenetic modifications in the heritability of multiple sclerosis","volume":"20","author":"Zhou","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0605","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1474-4422(14)70041-9","article-title":"Multiple sclerosis genetics","volume":"13","author":"Sawcer","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2015.05.008","article-title":"Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy","author":"Zhang","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.06.001_bb0615","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.molmed.2013.09.003","article-title":"Developing epigenetic diagnostics and therapeutics for brain disorders","volume":"19","author":"Qureshi","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2015.06.001_bb0620","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0165-5728(03)00131-0","article-title":"Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis","volume":"139","author":"Ilyas","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0625","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2011.08.002","article-title":"Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis","volume":"238","author":"Brennan","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0630","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0022-510X(86)90048-1","article-title":"Anti-glycolipid antibodies and their immune complexes in multiple sclerosis","volume":"75","author":"Kasai","year":"1986","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.06.001_bb0635","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-005-0655-9","article-title":"Predicting the outcome of optic neuritis: evaluation of r.isk factors after 30years of follow-up","volume":"252","author":"Nilsson","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0640","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jneuroim.2006.03.004","article-title":"IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles","volume":"175","author":"Malmestr\u00f6m","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0645","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2015.06.001_bb0650","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1351-5101.2003.00706.x","article-title":"Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus","volume":"11","author":"Baraczka","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0655","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2011.12.004","article-title":"Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients","volume":"244","author":"Wen","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0660","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1352458510382247","article-title":"Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis","volume":"17","author":"B\u00f6rnsen","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0665","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archneur.65.5.633","article-title":"Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis","volume":"65","author":"Braitch","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0670","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.06.001_bb0675","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0165-5728(02)00319-3","article-title":"Brain-derived neurotrophic factor in patients with multiple sclerosis","volume":"132","author":"Sarchielli","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0680","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/1352458511433303","article-title":"Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis","volume":"18","author":"Avsar","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0685","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/135245859800400603","article-title":"Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis","volume":"4","author":"Sellebjerg","year":"1998","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0690","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1191\/135248506ms1263oa","article-title":"Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis","volume":"12","author":"Brettschneider","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0695","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1191\/1352458506ms1288sr","article-title":"Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis","volume":"12","author":"Guimar\u00e3es","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0700","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/135245859800400326","article-title":"Are there indicators of remyelination in blood or CSF of multiple sclerosis patients?","volume":"4","author":"Massaro","year":"1998","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2015.06.001_bb0705","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0404.2010.01330.x","article-title":"Impact of cladribine on soluble adhesion molecules in multiple sclerosis","volume":"122","author":"Mitosek-Szewczyk","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2015.06.001_bb0710","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ana.410410307","article-title":"Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis","volume":"41","author":"Rieckmann","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.06.001_bb0715","doi-asserted-by":"crossref","first-page":"e12442","DOI":"10.1371\/journal.pone.0012442","article-title":"Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis","volume":"5","author":"Stoop","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.06.001_bb0720","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/1352458510364634","article-title":"Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis","volume":"16","author":"Gillett","year":"2010","journal-title":"Mult Scler"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T21:56:12Z","timestamp":1537566972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215001329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":144,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1568997215001329"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.06.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}